IVF is a popular treatments that aids couples with infertility problems, single mothers, and the LGBT community to procreate. The Russia IVF market is expected to witness a substantial growth rate in the future, owing to high incidence of infertility cases, emergent trend of delayed pregnancies among women, technological developments in IVF procedures, and increased incidence of gamete donations.
Growth of the market is further augmented by the low-cost clinical settings for IVF treatments in comparison to U.S., UK, and other established markets. Popularity of Russia for medical tourism, owing to advanced IVF facilities and treatment options, supplement the market growth. However, poor reimbursement policies associated with IVF treatment are anticipated to impede the market growth during the forecast period. Furthermore, rise in concern of single parents and same-sex couples in experiencing parenthood through artificial reproductive technology (ART), especially IVF, is expected to present numerous opportunities for market expansion.
The Russia IVF market is segmented based on end user, cycle type, type, drug, and mode of administration. Based on end user, it is divided into fertility clinics, hospitals, surgical centers, and clinical research institutes. The cycle type is classified into fresh IVF cycles (non-donor), thawed IVF cycles (non-donor), and donor egg IVF cycles. Based on type, the market is bifurcated into non-ICSI IVF cycles and ICSI-assisted IVF cycles. On the basis of drug, it is classified into clomiphene citrate, aromatase inhibitors, gonadotropins & gonadotropin-releasing hormone, follicle-stimulating hormone, progesterone, and others. Mode of administration includes oral, injectable, and vaginal modes.
KEY MARKET BENEFITS
This report provides a detailed quantitative analysis of the current trends in the Russia IVF market from 2014 to 2022 to identify the prevailing opportunities.
Market estimations are based on comprehensive analysis of the key developments in the industry.
In-depth analysis based on drugs and end users assists to understand the market and the strategic business planning.
The developmental strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By End User
Clinical Research Institutes
By Cycle Type
Fresh IVF Cycles (Non-donor)
Thawed IVF Cycles (Non-donor)
Donor egg IVF Cycles
Non-ICSI IVF Cycles
ICSI-assisted IVF Cycles
Gonadotropins & Gonadotropin-releasing Hormone
By Mode of Administration
KEY PLAYERS PROFILED
MD Medical Group
IVF Russia Agilent Technologies
The other players in the value chain include (profiles not included in the report):
EMD Serono, Inc.
Cooper Surgical, Inc.
Cook Medical, Inc.
Thermo Fisher Scientific, Inc.
1.1. EUROPE IVF MARKET (REVENUE AND NUMBER OF CYCLES)
1.2. RUSSIA IVF MARKET (REVENUE AND NUMBER OF CYCLES)
1.2.1. Market size and forecast
1.2.2. Russia IVF market, by end user
22.214.171.124. Market size and forecast
126.96.36.199. Fertility clinics
188.8.131.52. Surgical centers
184.108.40.206. Clinical research institutes
1.2.3. Russia IVF market, by cycle type
220.127.116.11. Market size and forecast
18.104.22.168. Fresh IVF cycles (non-donor)
22.214.171.124. Thawed IVF cycles (non-donor)
126.96.36.199. Donor egg IVF cycles
1.2.4. Russia IVF market, by type
188.8.131.52. Market size and forecast
184.108.40.206. Non-ICSI IVF cycles
220.127.116.11. ICSI-assisted IVF cycles
1.2.5. Russia IVF market by pharmacological modality
18.104.22.168. Key trends
22.214.171.124. Market size and forecast
126.96.36.199. Duration of therapy
188.8.131.52. Segmentation of drugs for IVF
184.108.40.206.1. Clomiphene citrate
220.127.116.11.2. Aromatase inhibitors
18.104.22.168.3. Gonadotropins & gonadotropin-releasing hormone (GnRH)
22.214.171.124.4. Follicle-stimulating hormone (FSH)
126.96.36.199. Mode of administration
1.2.6. Market dynamics
188.8.131.52.1. Rise in popularity of fertility tourism
184.108.40.206.2. Advanced IVF facilities and treatment options
220.127.116.11.1. Inadequate reimbursement policies
1.2.7. Regulatory issues, legislations, and authorities
1.2.8. Insurance reimbursement scenario
CHAPTER 2 COMPANY PROFILES
2.1. AVA-PETER CLINIC
2.1.1. Company overview
2.1.2. Company snapshot
2.1.3. Product portfolio
2.2. MD MEDICAL GROUP INVESTMENTS PLC (MD MEDICAL GROUP)
2.2.1. Company overview
2.2.2. Company snapshot
2.2.3. Operating business segments
2.2.4. Product portfolio
2.2.5. Business performance
2.2.6. Key strategic moves and developments
2.3. IVF RUSSIA (THE INTERNATIONAL CENTRE OF THE REPRODUCTIVE MEDICINES)
2.3.1. Company overview
2.3.2. Company snapshot
2.3.3. Operating business segments
In vitro fertilization (IVF) is an assisted reproductive technology (ART) that involves extraction of eggs, sample retrieval of sperm cells, followed by manual combination of an egg and sperm in laboratory settings to form an embryo. The embryo(s) is then transferred to the womans uterus for further gestation.
The Russia IVF market is driven by increase in incidence of infertility cases, emergent trend of delayed pregnancies among women, technological advancements in IVF procedures, and rise in gamete donation. However, insufficient reimbursement policies related to IVF treatment are anticipated to impede this growth. Moreover, growth in interest of single parents and same-sex couples to experience parenthood through ART, especially IVF, is expected to present various opportunities for market development.
The fertility clinics segment accounted for the highest share of the Russia IVF end user market in 2015, owing to the availability of wide range of fertility treatments under a single roof and applicable government reimbursements. The donor egg IVF cycle type segment is anticipated to witness the highest growth rate from 2016 to 2022. However, the fresh cycle (non-donor) is projected to dominate the cycle type market.
At present, gonadotropins & gonadotropin-releasing hormones dominate the drug segment of the market, and is expected to grow at a CAGR of 6.5% during the forecast period. This is attributable to the effectiveness and safety of this drug to stimulate ovulation during an IVF procedure.
Key Findings of the Russia in Vitro Fertilization (IVF) Market:
The fertility clinics end-user segment is anticipated to grow at the highest CAGR from 2016 to 2022 in terms of value as well as volume.
The fresh IVF cycle (non-donor) cycle type segment generated the highest revenue in 2015, and is expected to continue its dominance in the near future.
ICSI assisted IVF cycles dominated the Russia IVF market, and are projected to grow at a CAGR of 6.4%.
Donor egg IVF cycle type is expected to witness the highest growth rate in terms of value as well as volume during the forecast period.
The major companies profiled in the report include Ava-Peter Clinic, MD Medical Group, and IVF Russia (The International Centre of the Reproductive Medicines).